Sign in

    Katherine Xu

    Managing Director and Senior Equity Research Analyst at Citizens JMP

    Katherine Xu is a Managing Director and Senior Equity Research Analyst at Citizens JMP, specializing in biotechnology equity research with coverage of leading public and private biotech companies in areas such as oncology, rare diseases, and innovative therapeutics. She analyzes firms like Moderna, BioNTech, and CRISPR Therapeutics, maintaining a strong performance track record that includes a high ranking on TipRanks and above-average success rates for her stock recommendations. Xu began her career in equity research in the early 2000s, previously holding senior roles at firms such as Wedbush Securities and William Blair before joining Citizens JMP in the mid-2010s. She is FINRA-registered with Series 7, Series 63, and Series 86/87 licenses, and is recognized in the industry for her deep scientific expertise and accuracy in forecasting biotech sector trends.

    Katherine Xu's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Katherine Xu's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q3 2024

    Question

    Katherine Xu, on for Jon Wolleben, requested additional color on the FDA feedback for the paltusotine program in carcinoid syndrome and how the Phase III trial design might change relative to prior guidance.

    Answer

    Chief Medical and Development Officer Dr. Dana Pizzuti reported that the interaction with the FDA was very productive, with broad agreement. She noted the FDA provided perspective on endpoints and trial duration, which were anticipated and easily accommodated into the plan. The program remains on track with its previously stated timeline.

    Ask Fintool Equity Research AI